Human Genome Epidemiology Literature Finder
Records 1 - 21 (of 21 Records) |
Query Trace: Breast Neoplasms and DPYD[original query] |
---|
Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PloS one 2008 3 (12): e4003. Gross Eva, Busse Birgit, Riemenschneider Matthias, Neubauer Steffi, Seck Katharina, Klein Hanns-Georg, Kiechle Marion, Lordick Florian, Meindl Alfo |
Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients. Asian Pacific journal of cancer prevention : APJCP 2012 13 (4): 1553-6. Dogan Mutlu, Karabulut Halil G, Tukun Ajlan, Demirkazik Ahmet, Utkan Gungor, Yalcin Bulent, Dincol Dilek, Akbulut Hakan, Icli Fik |
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency]. Nederlands tijdschrift voor geneeskunde 2012 156 (48): A4934. Deenen Maarten J, Cats Annemieke, Mandigers Caroline M P W, Soesan Marcel, Terpstra Wim E, Beijnen Jos H, Schellens Jan H |
Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer. Pharmacogenomics 2013 Oct 14 (13): 1583-92. Alcazar-González Gregorio Antonio, Calderón-Garcidueñas Ana Laura, Garza-Rodríguez María Lourdes, Rubio-Hernández Gabriela, Escorza-Treviño Sergio, Olano-Martin Estibaliz, Cerda-Flores Ricardo Martín, Castruita-Avila Ana Lilia, González-Guerrero Juan Francisco, le Brun Stéphane, Simon-Buela Laureano, Barrera-Saldaña Hugo Alber |
Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers. British journal of cancer 2013 Oct 109 (9): 2347-55. Gross E, Meul C, Raab S, Propping C, Avril S, Aubele M, Gkazepis A, Schuster T, Grebenchtchikov N, Schmitt M, Kiechle M, Meijer J, Vijzelaar R, Meindl A, van Kuilenburg A B |
Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget 2016 Oct 7 (41): 66790-66808. Tecza Karolina, Pamula-Pilat Jolanta, Lanuszewska Joanna, Grzybowska E |
Highlight on DPYD gene polymorphisms and treatment by capecitabine (.). Scandinavian journal of clinical and laboratory investigation. Supplementum 2016 245 S30-3. Milano Géra |
New advances in DPYD genotype and risk of severe toxicity under capecitabine. PloS one 2017 12 (5): e0175998. Etienne-Grimaldi Marie-Christine, Boyer Jean-Christophe, Beroud Christophe, Mbatchi Litaty, van Kuilenburg André, Bobin-Dubigeon Christine, Thomas Fabienne, Chatelut Etienne, Merlin Jean-Louis, Pinguet Frédéric, Ferrand Christophe, Meijer Judith, Evrard Alexandre, Llorca Laurence, Romieu Gilles, Follana Philippe, Bachelot Thomas, Chaigneau Loic, Pivot Xavier, Dieras Véronique, Largillier Rémy, Mousseau Mireille, Goncalves Anthony, Roché Henri, Bonneterre Jacques, Servent Véronique, Dohollou Nadine, Château Yann, Chamorey Emmanuel, Desvignes Jean-Pierre, Salgado David, Ferrero Jean-Marc, Milano Géra |
Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients. Therapeutic drug monitoring 2018 May . Duley John A, Ni Ming, Shannon Catherine, Norris Ross L, Sheffield Leslie, Cowley David, Harris Marion, van Kuilenburg André B P, Helsby Nuala, George Rani, Charles Bruce |
Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget 2018 Feb 9 (10): 9114-9136. Tecza Karolina, Pamula-Pilat Jolanta, Lanuszewska Joanna, Butkiewicz Dorota, Grzybowska E |
Use of Germline Genetic Variability for Prediction of Chemoresistance and Prognosis of Breast Cancer Patients. Cancers 2018 12 10 (12): . Hlavac Viktor, Kovacova Maria, Elsnerova Katerina, Brynychova Veronika, Kozevnikovova Renata, Raus Karel, Kopeckova Katerina, Mestakova Sona, Vrana David, Gatek Jiri, Ostasov Pavel, Vaclavikova Radka, Soucek Pav |
Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy. Oncotarget 2017 Dec 8 (67): 112060-112075. Qin Fengxia, Zhang Huikun, Huang Yong, Yang Limin, Yu Feng, Liu Xiaoli, Fu Li, Gu Feng, Ma Yongj |
Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report. Frontiers in oncology 2019 3 9 139. Palmirotta Raffaele, Lovero Domenica, Delacour Hervé, Le Roy Audrey, Cremades Serge, Silvestris Fran |
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. Breast cancer research and treatment 2019 2 175 (2): 511-517. Stavraka Chara, Pouptsis Athanasios, Okonta Leroy, DeSouza Karen, Charlton Philip, Kapiris Matthaios, Marinaki Anthony, Karapanagiotou Eleni, Papadatos-Pastos Dionysis, Mansi Jani |
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast cancer research and treatment 2020 May . O'Donnell Peter H, Trubetskoy Vassily, Nurhussein-Patterson Ashley, Hall Julianne P, Nath Aritro, Huo Dezheng, Fleming Gini F, Ingle James N, Abramson Vandana G, Morrow P K, Storniolo Anna Maria, Forero Andres, Van Poznak Catherine, Liu Minetta C, Chang Jenny C, Merkel Douglas E, Peppercorn Jeffrey M, Rugo Hope S, Dees E Claire, Hahn Olwen M, Hoffman Philip C, Rosner Gary L, Huang R Stephanie, Ratain Mark J, Cox Nancy, Olopade Olufunmilayo I, Wolff Antonio C, Dolan M Eileen, Nanda Rita, |
Genetic 3'UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients. Scientific reports 2020 Mar 10 (1): 5736. Pamu?a-Pi?at Jolanta, T?cza Karolina, Kalinowska-Herok Magdalena, Grzybowska E |
Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives. Mutation research. Reviews in mutation research 2021 12 788 108391. Cura Yasmin, Pérez Ramírez Cristina, Sánchez Martín Almudena, Martínez Martínez Fernando, Calleja Hernández Miguel Ángel, Ramírez Tortosa María Del Carmen, Jiménez Morales Alber |
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021 11 24 (3): 483-494. García-Alfonso P, Saiz-Rodríguez M, Mondéjar R, Salazar J, Páez D, Borobia A M, Safont M J, García-García I, Colomer R, García-González X, Herrero M J, López-Fernández L A, Abad-Santos |
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase. Cancer drug resistance (Alhambra, Calif.) 2022 5 2 (3): 787-802. Merloni Filippo, Ranallo Nicoletta, Scortichini Laura, Giampieri Riccardo, Berardi Rossa |
Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy. JCO oncology practice 2022 3 18 (6): e958-e965. Koo Kyoin, Pasternak Amy L, Henry N Lynn, Sahai Vaibhav, Hertz Daniel |
Profiling of pharmacogenomic variants in CYP2D6 and DPYD in indigenous Arab breast cancer patients. Pharmacogenomics 2023 5 . Abdullah Alsulaiman, Hoyin Chu, Mohammed Al-Jumaan, Mohammed Alyahya, Yousef Al Marzooq, Fatmah Almulhim, Chittibabu Vatte, Areej Alnimer, Afnan Almuhanna, Amein Al-Ali, Saud H AlDubay |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source: